163 related articles for article (PubMed ID: 12528561)
1. [An experimental study on bone marrow purging in vitro for patients with chronic myelogenous leukemia].
Liu J; Jiang J; Zhang Y; Wu D; Yang G; Huang X; Wei X
Hua Xi Yi Ke Da Xue Xue Bao; 2001 Dec; 32(4):599-601. PubMed ID: 12528561
[TBL] [Abstract][Full Text] [Related]
2. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
[TBL] [Abstract][Full Text] [Related]
3. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
[TBL] [Abstract][Full Text] [Related]
4. Interferon-alpha and bcr-abl antisense oligodeoxynucleotides in combination enhance the antileukemic effect and the adherence of CML progenitors to preformed stroma.
Bellucci R; Sala R; De Propris MS; Cordone I; de Fabritiis P
Leuk Lymphoma; 1999 Nov; 35(5-6):471-81. PubMed ID: 10609784
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase.
de Fabritiis P; Petti MC; Montefusco E; De Propris MS; Sala R; Bellucci R; Mancini M; Lisci A; Bonetto F; Geiser T; Calabretta B; Mandelli F
Blood; 1998 May; 91(9):3156-62. PubMed ID: 9558370
[TBL] [Abstract][Full Text] [Related]
6. [Influence of IFN-alpha and IFN-alpha combined with GM-CSF on expression of the genes related to cell apoptosis of MNCs from bone marrow in CML patients].
Tang LJ; Chen HC; Peng XH
Hunan Yi Ke Da Xue Xue Bao; 2000 Dec; 25(6):570-2. PubMed ID: 12516408
[TBL] [Abstract][Full Text] [Related]
7. Cytokine treatment of human bone marrow activates anti-leukaemia effector cells: monitoring of purging by polymerase chain reaction and DNA analysis.
Dickinson AM; Middleton SL; Latham J; Dunn J; Thomas L; Proctor SJ
Leukemia; 1995 Mar; 9(3):444-9. PubMed ID: 7533866
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibition of chronic myelogenous leukemia cells by ODN-1, an aptameric inhibitor of p210bcr-abl tyrosine kinase activity.
Schwartz GN; Liu YQ; Tisdale J; Walshe K; Fowler D; Gress R; Bergan RC
Antisense Nucleic Acid Drug Dev; 1998 Aug; 8(4):329-39. PubMed ID: 9743470
[TBL] [Abstract][Full Text] [Related]
9. Enhanced elimination of Ph+ chromosome cells in vitro by combined hyperthermia and other drugs (AZT, IFN-alpha, TNF, and quercetin): its application to autologous bone marrow transplantation for CML.
Osman Y; Moriyama Y; Shibata A
Exp Hematol; 1995 May; 23(5):444-52. PubMed ID: 7720816
[TBL] [Abstract][Full Text] [Related]
10. Purging efficacy of ZnPcH₁-based photodynamic therapy on chronic myeloid leukemia bone marrow.
Huang H; Chen Y; Chen W; Wu Y
Int J Lab Hematol; 2011 Oct; 33(5):477-82. PubMed ID: 21457188
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system.
Mayotte N; Roy DC; Yao J; Kroon E; Sauvageau G
Blood; 2002 Dec; 100(12):4177-84. PubMed ID: 12393433
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors.
Verma UN; Bagg A; Brown E; Mazumder A
Bone Marrow Transplant; 1994 Feb; 13(2):115-23. PubMed ID: 8205079
[TBL] [Abstract][Full Text] [Related]
13. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
[TBL] [Abstract][Full Text] [Related]
14. Autologous transplantation therapy for chronic myelogenous leukemia.
Bhatia R; Verfaillie CM; Miller JS; McGlave PB
Blood; 1997 Apr; 89(8):2623-34. PubMed ID: 9108379
[No Abstract] [Full Text] [Related]
15. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides.
de Fabritiis P; Amadori S; Calabretta B; Mandelli F
Bone Marrow Transplant; 1993 Sep; 12(3):261-5. PubMed ID: 8241986
[TBL] [Abstract][Full Text] [Related]
16. Eilatin: a novel marine alkaloid inhibits in vitro proliferation of progenitor cells in chronic myeloid leukemia patients.
Einat M; Lishner M; Amiel A; Nagler A; Yarkorli S; Rudi A; Kashman Y; Markel D; Fabian I
Exp Hematol; 1995 Dec; 23(14):1439-44. PubMed ID: 8542929
[TBL] [Abstract][Full Text] [Related]
17. Fractionation of chronic myelogenous leukemia marrow cells by stroma adherence: implications for marrow purging.
Rizzoli V; Mangoni L; Piovani G; Garau D; Caramatti C; Almici C; Carlo-Stella C
Leuk Lymphoma; 1993; 11 Suppl 1():109-12. PubMed ID: 8251884
[TBL] [Abstract][Full Text] [Related]
18. Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.
Gewirtz AM
Leuk Lymphoma; 1993; 11 Suppl 1():131-7. PubMed ID: 7504543
[TBL] [Abstract][Full Text] [Related]
19. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
20. Interferon gamma is effective for BM purging in a patient with CML.
Becker M; Fabrega S; Belloc F; Rice A; Barbu V; Reiffers J
Bone Marrow Transplant; 1993 Aug; 12(2):155-8. PubMed ID: 8401363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
